If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
|Articles|September 25, 2015
Colon Cancer, Multiple Myeloma Drug Development Highlights Week in Specialty Pharmacy
Author(s)Davy James, Managing Editor
Top stories of the week on Specialty Pharmacy Times.
Advertisement
[<a href="//storify.com/pharmacytimes/colon-cancer-multiple-myeloma-drug-development-hig" target="_blank">View the story "Colon Cancer, Multiple Myeloma Drug Development Highlights Week in Specialty Pharmacy" on Storify</a>]
Advertisement
Related to this article
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice
5